Emma Hall
Institute of Cancer Research
Quality of lifeCancerInternal medicineRadiologyUrologySurgeryOncologyRandomized controlled trialMedical physicsClinical endpointProstateChemotherapyProstate cancerBladder cancerToxicityNuclear medicineRadiation therapyBreast cancerClinical trialMedicine
334Publications
57H-index
13.4kCitations
Publications 333
Newest
#1Sophie R. de Mol van Otterloo (UU: Utrecht University)H-Index: 1
Last. Corinne Faivre-Finn (University of Manchester)H-Index: 50
view all 36 authors...
Purpose null High-field magnetic resonance-linear accelerators (MR-Linacs), linear accelerators combined with a diagnostic magnetic resonance imaging (MRI) scanner and online adaptive workflow, potentially give rise to novel online anatomic and response adaptive radiation therapy paradigms. The first high-field (1.5T) MR-Linac received regulatory approval in late 2018, and little is known about clinical use, patient tolerability of daily high-field MRI, and toxicity of treatments. Herein we repo...
Source
#1Christopher M. Nutting (The Royal Marsden NHS Foundation Trust)H-Index: 69
#2Clare Griffin (ICR: Institute of Cancer Research)H-Index: 15
Last. Amen Sibtain (St Bartholomew's Hospital)
view all 30 authors...
BACKGROUND Radical (chemo)radiotherapy offers potentially curative treatment for patients with locally advanced laryngeal or hypopharyngeal cancer. We aimed to show that dose-escalated intensity-modulated radiotherapy (DE-IMRT) improved locoregional control. METHODS We performed a phase III open-label randomised controlled trial in patients with laryngeal or hypopharyngeal cancer (AJCC III-IVa/b, TNM 7). Patients were randomised (1:1) to DE-IMRT or standard dose IMRT (ST-IMRT) using a minimisati...
Source
#2Keith RooneyH-Index: 6
Last. S.A. BhideH-Index: 14
view all 14 authors...
Source
#1Sara Arce-GallegoH-Index: 2
#2Alba Llop-GuevaraH-Index: 7
Last. Claudia Bertan (ICR: Institute of Cancer Research)H-Index: 19
view all 25 authors...
Background: PARP inhibitors (PARPi) are approved for the treatment of metastatic prostate cancer (mPC) associated to various DNA damage repair (DDR) gene mutations; but clinical benefit differs among patients. Biomarkers of homologous recombination repair (HRR) deficiency may help refine patient stratification for a more precise therapy selection. We report an exploratory analysis from the TOPARP-B phase II clinical trial of olaparib in mPC (NCT01682772), investigating the predictive value of an...
Source
#1Douglas Brand (ICR: Institute of Cancer Research)H-Index: 5
#2Sarah C. Brüningk (ETH Zurich)H-Index: 5
Last. Sarah L. Gulliford (UCL: University College London)H-Index: 23
view all 12 authors...
Abstract Purpose Changes in fraction size of external beam radiotherapy (EBRT) exert non-linear impacts on subsequent toxicity. Commonly described by the linear-quadratic model, fraction size sensitivity of normal tissues is expressed by the α/β ratio. Here we study individual α/β ratios for different late rectal side effects after prostate EBRT. Methods and Materials The XXXXXXX trial (XX-REGISTRATION-NUMBER-XX) randomised men with non-metastatic prostate cancer 1:1:1 to 74Gy/37 fractions (Fr),...
2 CitationsSource
#1Robert Huddart (ICR: Institute of Cancer Research)H-Index: 83
#2Shaista Hafeez (ICR: Institute of Cancer Research)H-Index: 13
Last. Hybrid InvestigatorsH-Index: 1
view all 24 authors...
Purpose Hypofractionated radiation therapy can be used to treat patients with muscle-invasive bladder cancer unable to have radical therapy. Toxicity is a key concern, but adaptive plan-of the day (POD) image-guided radiation therapy delivery could improve outcomes by minimizing the volume of normal tissue irradiated. The HYBRID trial assessed the multicenter implementation, safety, and efficacy of this strategy. Methods HYBRID is a Phase II randomized trial that was conducted at 14 UK hospitals...
8 CitationsSource
#1Suzanne Carreira (ICR: Institute of Cancer Research)H-Index: 33
#2Nuria Porta (ICR: Institute of Cancer Research)H-Index: 12
Last. Johann S. de Bono (ICR: Institute of Cancer Research)H-Index: 124
view all 27 authors...
PARP inhibitors are approved for treating advanced prostate cancers (APCs) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B Phase II clinical trial samples, evaluating whole exome and low-pass whole genome sequencing and immunohistochemical assays evaluating ATM and RAD51 foci (testing homologous recombination repair function). BRCA1/2 germline and somatic pathogenic mutations associated with ...
1 CitationsSource
#1Syed A. Hussain (University of Sheffield)H-Index: 32
#2Nuria Porta (The Royal Marsden NHS Foundation Trust)
Last. Nicholas D. James (The Royal Marsden NHS Foundation Trust)H-Index: 66
view all 7 authors...
Source
#1Adham Hijab (The Royal Marsden NHS Foundation Trust)
#1A. Hijab (The Royal Marsden NHS Foundation Trust)
Last. Chris Parker (ICR: Institute of Cancer Research)H-Index: 83
view all 16 authors...
Abstract Background Radium-223 is a bone-seeking, alpha-emitting radionuclide used in metastatic castration resistant prostate cancer (mCRPC). Radium-223 increases the risk of fracture when used in combination with abiraterone and prednisolone. The risk of fracture in men receiving radium-223 monotherapy is unclear. Patients and Methods Prospective, multicentre phase II study of radium-223 in 36 men with mCRPC, and a reference cohort (n=36), matched for fracture risk, not treated with radium-223...
Source
#1A. WebsterH-Index: 2
#2Shaista Hafeez (ICR: Institute of Cancer Research)H-Index: 13
Last. Helen McNair (ICR: Institute of Cancer Research)H-Index: 30
view all 11 authors...
Abstract Aims Adaptive radiotherapy (ART) is an emerging advanced treatment option for bladder cancer patients. Therapeutic radiographers (RTTs) are central to the successful delivery of this treatment. The purpose of this work was to evaluate the image-guided radiotherapy (IGRT) and ART experience of RTTs before participating in the RAIDER trial. A plan of the day (PoD) quality assurance programme was then implemented. Finally, the post-trial experience of RTTs was evaluated, together with the ...
1 CitationsSource